As part of the collaboration, the US-based company will use its Library of Libraries for the discovery of new antibodies against Artisan Bio’s immunotherapy targets.

Meanwhile, Artisan will develop custom cell therapies using its STAR Guides and Immune Cell Engineering Foundry.

Twist Bioscience CEO and co-founder Emily Leproust said: “CRISPR presents a myriad of opportunities to revolutionize human health. Artisan has a unique approach that combines a deep understanding of this gene-editing technology with advanced AI analysis.

“Our collaboration with Artisan will leverage our innovative antibody discovery capabilities to help translate this cutting-edge approach into novel cell therapies.”

Under the terms of the partnership, Twist will get project fees for each programme along with upfront technology access.

The company will also be eligible for clinical, regulatory, and commercial milestones as well as royalties on product sales.